As of Feb 23
| +0.01 / +0.27%|
The 3 analysts offering 12-month price forecasts for ADMA Biologics Inc have a median target of 8.00, with a high estimate of 15.00 and a low estimate of 5.00. The median estimate represents a +111.64% increase from the last price of 3.78.
The current consensus among 3 polled investment analysts is to Buy stock in ADMA Biologics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.